2026-10-13T11:46:41Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33995331 2026-10-01T14:54:37Z category_67901 category_67907 portal_1154 item_type_7 month_year_10_2026

Congress presentation: IMS 2026 Elinzanetant improves Patient Global Impression of sleep disturbance severity and change in postmenopausal women with moderate-to-severe vasomotor symptoms: OASIS-1 Phase III actigraphy substudy Fiona C. Baker (9344517) Michael Kremliovsky (25156731) Adam Skubala (25156732) Christian Seitz (2722336) Cecilia Caetano (18563210) Ioanna Gkioni (21842866) Pauline M. Maki (7246670) Menopause Sleep PGI-S PGI-C PRO measures Actigraphy VMS Patient-reported outcomes <p dir="ltr">The OASIS-1 actigraphy substudy evaluated elinzanetant's effects on patient-perceived sleep disturbance vs placebo using Patient Global Impression of Severity (PGI-S) and Patient Global Impression of Change (PGI-C), patient-reported outcome measures capturing sleep problem severity and perceived change over time. Elinzanetant improved both objectively measured sleep continuity and patient-perceived sleep disturbance severity and change in postmenopausal women with VMS, supporting convergence across actigraphy and patient-reported outcomes.</p> 2026-10-01T14:54:37Z Text Presentation 10.71943/bayer.figshare.33995331.v1 https://figshare.com/articles/presentation/Congress_presentation_IMS_2026_Elinzanetant_improves_Patient_Global_Impression_of_sleep_disturbance_severity_and_change_in_postmenopausal_women_with_moderate-to-severe_vasomotor_symptoms_OASIS-1_Phase_III_actigraphy_substudy/33995331 CC BY-ND